**MEDICAL POLICY – 2.01.71**

**Nonpharmacologic Treatment of Rosacea**

**BCBSA Ref. Policy:** 2.01.71

**Effective Date:** March 1, 2019

**Last Revised:** Feb. 5, 2019

**Replaces:** 2.01.519

**RELATED MEDICAL POLICIES:**

10.01.514  Cosmetic and Reconstructive Services

Select a hyperlink below to be directed to that section.

- POLICY CRITERIA  |  CODING  |  RELATED INFORMATION
- EVIDENCE REVIEW  |  REFERENCES  |  HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

---

**Introduction**

Rosacea is a long-lasting skin condition that affects adults. It usually affects more women than men. And while it can affect anyone, it usually occurs more frequently in people with fair skin. Typically, rosacea affects adults between the ages of 20 and 60. It often creates redness on the cheeks, nose, chin, or forehead. It can also affect the neck, chest, scalp, or ears. The redness tends to become more persistent over time, with little blood vessels appearing. Bumps and pimples may also develop. In some people, the nose becomes swollen or bumpy due to extra tissue. (This is known as rhinophyma.) While rosacea can’t be cured, medication (pharmacologic treatment) is effective in controlling symptoms. Other treatments, such as laser or light therapy or removing the top layers of the skin (dermabrasion), have been tried. These types of rosacea treatments are investigational (unproven). Published medical studies do not conclusively prove that they work as well as or better than using medication. More and longer studies are needed.

---

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

---

**Policy Coverage Criteria**
Service | Investigational
---|---
Nonpharmacologic treatment of rosacea | Nonpharmacologic treatment of rosacea, including but not limited to laser and light therapy, dermabrasion, chemical peels, surgical debulking, and electrosurgery, is considered investigational.

**Coding**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17106</td>
<td>Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq. cm</td>
</tr>
<tr>
<td>17107</td>
<td>Destruction of cutaneous vascular proliferative lesions (eg, laser technique); 10.0 to 50.0 sq. cm</td>
</tr>
<tr>
<td>17108</td>
<td>Destruction of cutaneous vascular proliferative lesions (eg, laser technique); over 50.0 sq. cm</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

**Related Information**

N/A

**Evidence Review**
Description

Rosacea is a chronic, inflammatory skin condition without a known cure; the goal of treatment is symptom management. Nonpharmacologic treatments, including laser and light therapy as well as dermabrasion, which are the focus of this policy, are proposed for patients who do not want to use or are unresponsive to pharmacologic therapy.

Background

*Rosacea*

Rosacea is characterized by episodic erythema, edema, papules, and pustules that occur primarily on the face but may also be present on the scalp, ears, neck, chest, and back. On occasion, rosacea may affect the eyes. Patients with rosacea tend to flush or blush easily. Because rosacea causes facial swelling and redness, it is easily confused with other skin conditions, such as acne, skin allergy, and sunburn.

Rosacea mostly affects adults with fair skin between the ages of 20 and 60 years and is more common in women, but often most severe in men. Rosacea is not life-threatening, but if not treated, may lead to persistent erythema, telangiectasias, and rhinophyma (hyperplasia and nodular swelling and congestion of the skin of the nose). The etiology and pathogenesis of rosacea are unknown but may result from both genetic and environmental factors. Some theories on the causes of rosacea include blood vessel disorders, chronic *Helicobacter pylori* infection, *Demodex folliculorum* (mites), and immune system disorders.

While the clinical manifestations of rosacea do not usually impact the physical health status of the patient, psychological consequences from the most visually apparent symptoms (ie, erythema, papules, pustules, telangiectasias) that may impact the quality of life. Rhinophyma, an end-stage of chronic acne, has been associated with obstruction of nasal passages and basal cell carcinoma in rare, severe cases. The probability of developing nasal obstruction or basal or squamous cell carcinoma with rosacea is not sufficient to warrant preventive removal of rhinophymatous tissue.
**Treatment**

Rosacea treatment can be effective in relieving signs and symptoms. Treatment may include oral and topical antibiotics, isotretinoin, β-blockers, clonidine, and anti-inflammatories. Patients are also instructed on various self-care measures such as avoiding skin irritants and dietary items thought to exacerbate acute flare-ups.

Nonpharmacologic therapy has also been tried in patients who cannot tolerate or do not want to use pharmacologic treatments. To reduce visible blood vessels, treat rhinophyma, reduce redness, and improve appearance, various techniques such as laser and light therapy, dermabrasion, chemical peels, surgical debulking, and electrosurgery have been used. Various lasers used include low-powered electrical devices and vascular light lasers to remove telangiectasias, co2 lasers to remove unwanted tissue from rhinophyma and reshape the nose, and intense pulsed lights that generate multiple wavelengths to treat a broader spectrum of tissue.

**Summary of Evidence**

For individuals with rosacea who receive nonpharmacologic treatment (eg, laser therapy, light therapy, dermabrasion), the evidence includes several small randomized, split-face design trials. The relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. The randomized controlled trials evaluated laser and light therapy. No trials assessing other nonpharmacologic treatments were identified. None of the randomized controlled trials included a comparison group of patients receiving a placebo or pharmacologic treatment; therefore, these trials do not offer evidence on the efficacy of laser or light treatment compared with alternative treatments. There is a need for randomized controlled trials that compare nonpharmacologic treatments with placebo controls and with pharmacologic treatments. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 1.
Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03211585</td>
<td>Evaluation Of The Effect Of The Perfecta V-Beam Laser On Rosacea (Facial Redness, Telangiectasias And Photodamage)</td>
<td>20</td>
<td>Dec 2018</td>
</tr>
<tr>
<td>NCT03194698</td>
<td>Efficacy of Intense Pulsed Light Treatment of Dry Eye and Ocular Rosacea</td>
<td>20</td>
<td>Dec 2018</td>
</tr>
<tr>
<td>NCT02075671</td>
<td>Photodynamic Therapy for Papulopustular Rosacea</td>
<td>30</td>
<td>Feb 2019</td>
</tr>
</tbody>
</table>

NCT: national clinical trial

* Denotes industry-sponsored or cosponsored trial

Practice Guidelines and Position Statements

American Acne and Rosacea Society

The American Acne and Rosacea Society (2014) issued consensus recommendations on the management of rosacea.9 The Society stated that lasers and intensely pulsed light devices could improve certain clinical manifestations of rosacea that have not responded to medical therapy. The recommendations indicated that these therapies would have to be repeated intermittently to sustain improvement.

American Academy of Dermatology

The American Academy of Dermatology (AAD) (2017) released online guidance for treatment and management of rosacea.10 The AAD encouraged patients to identify their triggers to minimize symptoms, including protection from exposure to the sun, heat, stress, alcohol, and spicy foods. The AAD indicated that laser or light therapy may be used to reduce redness and that laser resurfacing may be used to remove thickening skin. The AAD also stated that “researchers continue to study how lasers and light treatments can treat rosacea. As we learn more, these devices may play a bigger role in treating rosacea.”
**Rosacea Consensus Panel**

The Rosacea Consensus panel (2017), comprised of international experts including representatives from the United States, published recommendations for rosacea treatment.\(^{11}\) The panel agreed that treatments should be based on phenotype. Intense pulsed light and pulsed dye laser were recommended for persistent erythema, but not for transient erythema. Intense pulsed light and lasers were also recommended for telangiectasia rosacea.

**National Institutes for Health and Care Excellence**

The National Institutes for Health and Care Excellence (2017) published online pathways addressing skin damage and skin conditions.\(^{12}\) Pathways provide guidance on the use of topical agents to manage rosacea. There are no pathways, guidance, or recommendations on nonpharmacologic treatments for rosacea.

**Medicare National Coverage**

There is no national coverage determination.

**Regulatory Status**

Several laser and light therapy systems have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for various dermatologic indications, including rosacea. For example, rosacea is among the indications for:

- Candela® pulse dye laser system (Candela)
- Lumenis® One Family of Systems IPL component (Lumenis)
- Harmony® XL multi-application platform laser device (Alma Lasers, Israel)
- UV-300 Pulsed Light Therapy System (New Star Lasers)
• CoolTouch® PRIMA Pulsed Light Therapy System (New Star Lasers).

Food and Drug Administration product code: GEX.

References

History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/01/18</td>
<td>Policy reinstated, approved February 13, 2018, effective June 1, 2018. This policy was previously deleted, but now replaces policy 2.01.519. Nonpharmacologic treatment of rosacea is considered investigational.</td>
</tr>
<tr>
<td>06/01/18</td>
<td>Minor update; removed note and link to previous policy 2.01.519 which has been deleted.</td>
</tr>
<tr>
<td>03/01/19</td>
<td>Annual Review, approved February 5, 2019. Policy updated with literature review through October 2018; references 11 added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)
• Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room S09F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Arabic):
يحتوي هذا الإشعار على معلومات مهمة يتم تزويدك بها مجانًا في إشارة إلى القيود على بناء التغطية في هذا الإشعار. يمكن أن تكون هناك نقصان في تغطية التأمين الصحي الذي يمكن أن يستلزم التدفق الكافي. تحقق من الخطوط على هذه المعلومات والمتطلبات كلك ما ذكرت أعلاه. إتصل ب 800-722-1471 (TTY: 800-842-5357).

Chinese (Chinese):
本通知有重要信息。本通知可能有关您透过 Premera Blue Cross 提交的申请或保险的重要信息。本通知内可能有重要日期。您可能需要在特定日期之前采取行动。以保留您的健康保险或费用补贴。您有权利免费以您的母语得到本讯息和帮助。请拨电话 800-722-1471 (TTY: 800-842-5357).

Oromo (Cushite):

This notification contains important information. Please read it carefully. You may receive important dates for maintaining your health or assistance until termination of the policy or payment of premiums. You may call 800-842-5357 for assistance. For the hearing impaired, please call 800-722-1471 (TTY: 800-842-5357).

Premera Blue Cross is the provider of the policy. Important dates may appear in this alert. Please note the following information:

- If you have questions about your application or coverage, contact Premera Blue Cross. There may be important terms applicable to the issuance or change of coverage.
- Premera Blue Cross may notify you of important dates in the policy or notification. You may call 800-842-5357 for assistance. For the hearing impaired, please call 800-722-1471 (TTY: 800-842-5357).
- For more information, visit www.premera.com.
- To make an online payment, go to www.premera.com.
- For customer service, please call 800-842-5357.

Premera Blue Cross

800-842-5357 (TTY: 800-722-1471)